FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to apitope peptides, and can be used in medicine for the treatment of a demyelinating disease, such as multiple sclerosis. Peptide fragments are obtained from myelin oligodendrocyte glycoprotein (MOG): MOG 44–58: FSRVVHLYRNGKDQD (SEQ ID No. 3) and 45–59: SRVVHLYRNGKDQDG (SEQ ID No. 4).
EFFECT: invention provides for the production of MOG peptide apitope, capable of binding to the MHC molecule in vitro and being presented to a T-cell without antigen processing.
8 cl, 7 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE | 2014 |
|
RU2667428C2 |
| PEPTIDES | 2014 |
|
RU2676149C2 |
| COMPOSITION | 2015 |
|
RU2773344C2 |
| COMPOSITION | 2015 |
|
RU2728963C2 |
| RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
| PEPTIDE FROM THE COMPOSITION OF THE IMMUNOGLOBULIN HUMAN HEAVY CHAIN, SUITABLE FOR TREATMENT OF MULTIPLE SCLEROSIS | 2016 |
|
RU2646817C1 |
| LIPOSOMES CONTAINING OLIGOPEPTIDE FRAGMENTS OF MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION AND METHOD FOR MULTIPLE SCLEROSIS TREATMENT | 2013 |
|
RU2639497C2 |
| PEPTIDE CONJUGATED PARTICLES | 2013 |
|
RU2669346C2 |
| IMMUNOGENIC PEPTIDES FOR APPLICATION FOR PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AUTOIMMUNE DISEASES, THE IMMUNE RESPONSES TO ALLOGENEIC FACTORS, ALLERGIC DISEASES, TUMOUR, TRANSPLANT REJECTION AND IMMUNE RESPONSES AGAINST VIRAL VECTORS USED FOR GENETIC THERAPY OR GENETIC VACCINATION | 2011 |
|
RU2615460C2 |
| ACTH-LIKE PEPTIDE WITH IMMUNOSUPRESSOR FUNCTION | 2017 |
|
RU2681317C1 |
